Stockreport

Uvax Bio Announces Interim Results from a Phase 1 Clinical Trial Evaluating its HIV-1 Vaccine [Yahoo! Finance]

Dynavax Technologies Corporation  (DVAX) 
Last dynavax technologies corporation earnings: 3/11 04:10 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.dynavax.com
PDF The trial also demonstrated robust immune responses, with 100% of subjects showing antibody responses after two priming doses. The vaccine uses Uvax Bio's proprietary 1c [Read more]